Cognizant is advancing the application of generative AI (genAI) technology through the NVIDIA BioNeMo platform to help speed up drug discovery in the life sciences industry.

Traditional drug discovery methodologies are process-intensive, entailing the analysis of a huge amount of scientific literature and clinical data to gain relevant insights. They are also costly, time-consuming and have a high rate of failure. By leveraging gen AI technologies, clinical researchers can rapidly sift through extensive datasets, more accurately predict interactions between drug compounds, and create new, viable drug development pathways, says a Cognizant release.

Cognizant collaborates with global firms in the area of pharmaceuticals, biotech and medical devices, across the length of the life sciences value chain — from R&D to digital health. The company said its life sciences offerings support more than 120 global manufacturing lines and 18 million patients.

Related Topics
comment COMMENT NOW